Acrongenomics Inc., a Swiss life science venture company and Molecular Vision Ltd., a spin-out from the Imperial College London, said they have signed a memorandum of understanding to jointly develop diagnostic devices for diabetes, drug abuse, STDs and cardiovascular diseases.
Both companies didn’t disclose the financial details of the agreement but added the collaboration will be using Molecular Vision's diagnostic chips which are based on a technology that incorporate microfluidics and organic semiconductor devices (light emitting diodes and photodetectors). The two companies are targeted at a testing market that is estimated to reach $18 billion by 2010 (BCC Research).
Moelcular Vision is co-founded by Professor
Andrew de Mello, who is a professor of Chemical Nanosciences in the Department
of Chemistry at
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
